A subset of upper urinary tract urothelial cell carcinomas (UUC), arising sporadically or as a manifestation of hereditary non-polyposis colorectal cancer, displays microsatellite instability (MSI). MSI tumours are characterized by defective mismatch repair and accumulation of frameshift mutations in numerous genes harbouring repeats in their coding sequences. We have evaluated the incidence of MSI in UUC and the intratumoral distribution of mutations in 13 candidate target genes. A total of 58 unselected UUC were screened for MSI using the panel of five mononucleotide markers recently recommended by the National Cancer Institute for a precise MSI assessment. Four tumours displayed MSI (7%), among which at least three had alterations in the genes MSH3, BAX, MRE11, RAD50. Mutations in genes involved in key cellular pathways (ATR, DNA-PKcs, MBD4, TCF-4, MSH6, and BLM) were further detected. BAX and MRE11 mutations tend to present homogeneously within the three MSI UUC. Immunohistochemistry (MLH1, MSH2, MSH6) showed that loss of mismatch repair protein expression occurred in all MSI UUC defining the gene defect and that MRE11 and RAD50 mutations were associated with their concomitant loss expression. In conclusion, MSI UUC represent a small proportion of UUC in which BAX and MRE11 mutations are frequent and may play a role early in UUC tumorigenesis.
Introduction
Urothelial cell carcinomas are the fourth most common cancer being responsible for 10% of cancer-related death. The vast majority of urothelial cell carcinomas develop in the bladder, but 5% arise in the upper urinary tract (UUT) that is in the calyx, renal pelvis and ureter. UUT urothelial cell carcinomas (UUC) generally develop sporadically or within the hereditary non-polyposis colorectal cancer syndrome (HNPCC) (Vasen et al., 1996 (Vasen et al., , 1999 Sijmons et al., 1998; Aarnio et al., 1999; Aben et al., 2002) . HNPCC is an autosomal dominantly inherited disorder of cancer susceptibility (mostly colorectal and endometrial cancer) caused by a germline mutation in one of the mismatch repair (MMR) genes (Peltoma¨ki and Vasen, 1997) . The underlying mechanism of MMR-deficient tumour carcinogenesis reflects the accumulation of somatic frameshift mutations at repeated sequences located within the coding regions of target genes involved in key cellular pathways (Duval and Hamelin, 2002; Woerner et al., 2003) . The process involved in the selection of target genes appears to be somehow tissue-specific, with the mutation profiles differing between gynaecological and gastrointestinal cancers Woerner et al., 2003) .
Microsatellite instability (MSI) resulting from the underlying MMR defect is observed in most HNPCC tumours and in some sporadic cancers. In order to standardize MSI analyses, a first Bethesda consensus meeting recommended the use of five markers (two mononucleotide and three dinucleotide repeats) (Boland et al., 1998) . Because this method led to misclassification of a number of MSI colorectal cancers, the National Cancer Institute recently recommended the use of a fluorescent pentaplex PCR of mononucleotide repeats that has been shown to improve the gold standard of MSI detection in colorectal cancer (Umar et al., 2004) . These markers have been shown to establish tumour MSI status with clear interpretation of data and 100% specificity and sensitivity with no need for matched normal tissue (Suraweera et al., 2002; Buhard et al., 2004) . Few studies addressed the MSI status of UUC; they were performed using the original or a modified Bethesda panel and reported dramatic variations in the incidence rate (4-31%) Hartmann et al., 2002 Hartmann et al., , 2003 Catto et al., 2003; Roupret et al., 2004; Ericson et al., 2005) . Moreover, extensive analyses of mutational targets of MSI in UUC are not available to date. With this study, we aimed at evaluating the incidence of MSI in 58 UUC using for the first time the simple and accurate pentaplex PCR of quasi-monomorphic mononucleotide markers recently recommended by the NCI to phenotype MSI tumours (Umar et al., 2004) (Table 1) .
Four of the 58 tumours (7%) displayed widespread MSI, with at least four of the five markers tested being affected, with two tumours (No. 1 and 4) arising in HNPCC patients (Table 1) (Umar et al., 2004) . Among the 54 MSS tumours, three showed variations at a single marker, of which two corresponded to true instability (No. 17 and 30) ; in the remaining tumour (No. 33), the possibility of a rare polymorphism could not be unambiguously established in absence of corresponding germline DNA (Suraweera et al., 2002) . A total of 25 tumours (four MSI, two with variants at 1 locus and 19 MSS) have been further analysed using the original Bethesda panel leading to identical results. Whereas the four MSI tumours displayed MSI at all three dinucleotide loci (D2S123, D5S346, D17S250), no instability (Ericson et al., 2005) , but is significantly lower than the majority of the others, reporting 21-31% MSI-H tumours Hartmann et al., 2002; Catto et al., 2003; Roupret et al., 2004) . Although these studies had also been carried out on unselected UUC, the Bethesda panel used was significantly modified with the frequent inclusion of the BAT40 mononucleotide marker, as well as a number of additional dinucleotide markers. Several reasons may account for the discrepancies: (i) the interpretation of dinucleotide repeat profiles is difficult and generally leads to overclassification of tumours into MSI-H (Dietmaier et al., 1997) ; (ii) dinucleotide markers are less sensitive than mononucleotide markers, notably in case of MSH6 defect (Verma et al., 1999) ; (iii) the criteria used to define MSI were also less stringent than those defined for MSI colorectal cancer (Boland et al., 1998) . Because the sizes of allelic shifts in MSI UUC tumours were small (varying from 2 to 8 bp), we recommend the concomitant analysis of the normal counterpart DNA for MSI screening of these tumours, as in the case of endometrial tumours (Suraweera et al., 2002) .
Multiple tumour sites could be analysed in 17 cases; they were homogeneous with regard to the MSI status, indicating that the MMR defect is the first underlying molecular genetic event, consistent with loss of expression of either MSH2 or MLH1 in urothelial dysplasia in patients with MSI UUC (Hartmann et al., 2002) .
In the MSI HNPCC tumours (No. 1 and 4), the immunohistochemical expression of both MSH2 and MSH6 was lost, whereas MLH1 expression was retained, identifying the MSH2 germline defect (data not shown) (Parc et al., 2004) . In the other two MSI tumours, MLH1 expression was lost, with normal MSH2 and MSH6 expression. Considering the absence of medical family history in these cases, they are likely to be sporadic resulting from aberrant methylation of the MLH1 promoter, a common mechanism of MMR inactivation in sporadic MSI colorectal cancers (Kane et al., 1997; Herman et al., 1998) .
We further investigated the mutational status of 13 candidate target genes in multiple tumour sites in the four MSI UUC, as well as in the three tumours that displayed variants at a single locus. All MSI tumours displayed alterations in the repeated tracts in contrast to the other tumours in which no mutation could be detected (Table 2 ). Mutations were found in all genes, with the exception of BRCA1 and BRCA2, two genes that were further excluded from the calculation of the overall mutation rate. MSI tumours showed mutations in two (18%) to seven (63%) of the 11 target genes. We have detected MSH3 mutations in all MSI tumours and mutations of BAX, MRE11 and RAD50 in three of them, showing that these genes are frequent targets of MSI-driven mutations. Mutations of TGFb-RII, TCF-4, MSH6, MBD4, and ATR were found in two of the four tumours, whereas DNA-PKcs and BLM were mutated in only one tumour. In contrast to MSH3, RAD50, TGFb-RII, MSH6, and MBD4 whose mutations displayed heterogeneous intratumoral distribution, mutations of BAX, ATR and MRE11 tend to be present in multiple tumour sites (Table 2 and Figure 1) . Interestingly, the analyses of tumours No. 4-R1 and 4-R2, two e According to the PCR pentaplex using five mononucleotide markers: MSS, microsatellite stable versus MSI, microsatellite instability. When there were less than five amplified loci, the number of analysed loci is indicated in brackets. (Table 2 ). In the only previous study that addressed the characterization of MSI target genes, five candidate genes were investigated in 15 MSI UUC, where mutations were detected in MSH6 (38%), TGFb-RII (23%), BAX (23%), and MSH3 (15%), but not in IGF-RII (Hartmann et al., 2002) . Our study emphasizes the interest of performing mutational analysis of target genes in multiple tumour sites of each tumour rather than in a single site because this approach allows the detection of mutations occurring in only a part of the tumour. In addition, the necessary macrodissection on tissue blocks results in an enrichment of the tumour contingent as illustrated by the amplification profiles of the markers used to detect MSI, thus further optimizing conditions for detecting mutations in target genes (Brennetot et al., 2005) . Moreover, it is of importance to screen for mutations in multiple tumour sites because a homogeneous intratumoral mutation is in favour of its early involvement in tumorigenesis, as in the case of TGFb-RII and BAX in colorectal MSI tumours (AbdelRahman et al., 1999; Barnetson et al., 2000) . The low frequency and the heterogeneous intratumoral distribution of TGFb-RII mutations observed in our study argue against the participation of TGFb-RII in the initial transformation event of MSI UUT tumours (Wang et al., 1995; Hartmann et al., 2002) . In contrast, BAX and MRE11 mutations are frequent in UUC and tend to have a homogeneous intratumoral pattern suggesting that they may be selected early and participate in the tumour process. BAX, a proapoptotic member of the Bcl-2 family, is one of the most frequently inactivated genes in MSI colon carcinomas. Its deficiency has been A10  A9  G8  C8  A8  A10  T8  A8  A9  T11  A9  A10 A total of 13 target genes, chosen either because they were frequent targets for MSI-driven mutations in MSI tumours of various locations or because they play key roles in the maintenance of the genome integrity, were investigated at multiple tumour sites in MSI UUT tumours (Duval & Hamelin, 2002; Woerner et al., 2003) . With the exception of MRE11, all mononucleotide repeats studied were located in the coding sequence, where insertion/deletion mutations lead to the synthesis of a truncated protein. A mutation in the intronic MRE11 Poly (T)11 tract impairs the correct splicing process leading to a strong decrease in the MRE11 protein level (Giannini et al., 2002) . The presence of mutations in the mononucleotide repeats contained in the 13 selected genes was determined as described (Jacob et al., 2005) . Oligonucleotide sequences and protocol details are available upon request. Numerous normal DNA samples were used to establish the peak size and profile patterns of each gene. All PCR with abnormal profiles were repeated at least twice in independent PCR to confirm the presence of a mutation. For each gene, mutations were scored as present (black), absent (grey) or not determined (white). The number of tumours with mutations is indicated for each gene. The mutation frequency of each tumour site represents the percentage of mutations in the target genes studied, excluding BRCA1 and BRCA2.
shown to accelerate tumour growth and decrease apoptosis (Rampino et al., 1997; Ionov et al., 2000; Duval and Hamelin, 2002; Woerner et al., 2003) . MRE11 and RAD50, two genes frequently altered in MSI gastrointestinal tumours, forms together with NBS1 a complex that plays a major role in DNA damage signalling, DNA repair and cell cycle control (Kim et al., 2001; Giannini et al., 2002) . In order to evaluate the potential impact of mutations in the MRE11 and RAD50 genes, we have performed an immunohistochemical study on the four MSI UUC cases ( Figure 2 ). As previously described in colorectal cancer, we have shown that all UUC having mutations in either MRE11 or RAD50 demonstrated a clear reduced expression of both MRE11 and RAD50 proteins compared to the normal tissue. This suggests Figure 1 Examples of the detection of frameshift mutations in target gene mononucleotide repeated sequences. The regions encompassing the repeated sequences were amplified by PCR using fluorescent primers and migrated on an ABI3100 genetic analyser (Applied Biosystems). The profiles were analysed using the GeneScan 3.1 software. The wild-type allele is shown in plain, and an arrow indicates the mutated alleles. Figure 2 Immunohistochemical staining for MRE11 and RAD50 proteins in MSI UUT tumours. The 4-mm sections from formalinfixed, paraffin-embedded tissues were incubated after microwave antigen retrieval (pH 7.3) with a mouse monoclonal antibody against RAD50 (clone 13B3/2C6, 1:50 dilution, Genetex, San Antonio, TX) or a rabbit polyclonal antibody against MRE11 (1:300; Novus Biologicals, Littleton, CO). The immunoreactivity was revealed with the EnVision TM system (DakoCytomation, Glostrup, Denmark). For both antibodies, only nuclear staining was taken into account. In all cases analysed, the normal urothelium and renal parenchyma flanking the tumoral tissue served as internal positive control. that the MRE11/RAD50/NBS1 complex function may be impaired in MSI UUC (Giannini et al., 2002 (Giannini et al., , 2004 Ottini et al., 2004) . Loss of expression of both proteins was diffuse in the case (No. 1) displaying homogeneous RAD50 mutation. This reflects the fact that frameshift RAD50 mutations result in the synthesis of a truncated protein that is rapidly degraded, together with its partner MRE11. In the remaining three cases, loss of MRE11/RAD50 expression was restricted to a part of the tumour, although two of them (No. 3 and 4) exhibited MRE11 mutations in every tumour site (Figure 2 ). Yet, the consequences of the mutations occurring in the intronic MRE11 poly(T)11 tract are less clear-cut. To strongly impair MRE11 splicing, mutations ought to be bi-allelic and shortening should preferably be of at least two bases (Giannini et al., 2004) .
Hence, we propose that BAX and MRE11 may be real target genes that play a prominent role in MSI UUC progression. Consistent with this hypothesis, BAX and MRE11 were the only two alterations found in the first recurrence of one UUC case, whereas the second recurrence displayed additional alterations in numerous genes.
Based on this study, we recommend the use of the mononucleotide repeat pentaplex PCR to test MSI in UUC. By improving and optimizing MSI detection in UUC, this methodological approach may help in clarifying the role of MSI in UUC in terms of clinical behaviour and oncogenic pathway. Our data provide further insights into the identification of candidate genes whose inactivation may be suspected of being involved in MSI UUC.
